Findings

What do systematic reviews say?

4,811 questions · 70,850 findings · 5,139 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 21.4%GRADE not reported 6,479 · 9.1%Very low 17,330 · 24.5%Low 17,814 · 25.1%Moderate 11,056 · 15.6%High 2,997 · 4.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Treatment time (minutes) · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Quality of life · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Serum deposition Cmax · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

FEV1 · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Time to next exacerbation · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Participant satisfaction or preference · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

FEV1: change in FEV1 % predicted · children and adults with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intervention not reported

Treatment time (minutes) · children and adults with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 932 participants
Very low

Intervention not reported

Quality of life · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Serum deposition Cmax · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · children and adults with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 922 participants
Very low

Intervention not reported

FEV1 · children and adults with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1146 participants
Low

Intervention not reported

Time to next exacerbation · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Participant satisfaction or preference · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Treatment time · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Quality of life · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Serum deposition Cmax · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Time to next exacerbation · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found